Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Novartis
Moodys
UBS
Express Scripts
Dow
Baxter
Merck
US Department of Justice
Boehringer Ingelheim
Fuji

Generated: October 23, 2017

DrugPatentWatch Database Preview

SANCTURA Drug Profile

« Back to Dashboard

Which patents cover Sanctura, and what generic Sanctura alternatives are available?

Sanctura is a drug marketed by Allergan and is included in two NDAs. There are five patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in SANCTURA is trospium chloride. There are sixteen drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the trospium chloride profile page.

Summary for Tradename: SANCTURA

US Patents:0
Applicants:1
NDAs:2
Bulk Api Vendors: see list28
Clinical Trials: see list5
Patent Applications: see list596
Drug Prices:see details
DailyMed Link:SANCTURA at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan
SANCTURA
trospium chloride
TABLET;ORAL021595-001May 28, 2004DISCNYesNo► Subscribe► Subscribe► Subscribe
Allergan
SANCTURA XR
trospium chloride
CAPSULE, EXTENDED RELEASE;ORAL022103-001Aug 3, 2007DISCNYesNo► Subscribe► Subscribe ► Subscribe
Allergan
SANCTURA XR
trospium chloride
CAPSULE, EXTENDED RELEASE;ORAL022103-001Aug 3, 2007DISCNYesNo► Subscribe► Subscribe ► Subscribe
Allergan
SANCTURA XR
trospium chloride
CAPSULE, EXTENDED RELEASE;ORAL022103-001Aug 3, 2007DISCNYesNo► Subscribe► Subscribe ► Subscribe
Allergan
SANCTURA XR
trospium chloride
CAPSULE, EXTENDED RELEASE;ORAL022103-001Aug 3, 2007DISCNYesNo► Subscribe► SubscribeY ► Subscribe
Allergan
SANCTURA XR
trospium chloride
CAPSULE, EXTENDED RELEASE;ORAL022103-001Aug 3, 2007DISCNYesNo► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for SANCTURA

Drugname Dosage Strength RLD Submissiondate
trospium chlorideExtended-release Capsules60 mgSanctura XR3/2/2009
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Healthtrust
Medtronic
Covington
AstraZeneca
Federal Trade Commission
Cipla
Argus Health
Novartis
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot